Using genetically modified mouse models, we report here that p53 upregulated modulator of apoptosis (Puma) and Bcl-2 interacting mediator of cell death (Bim), two pro-apoptotic members of the B-cell lymphoma protein-2 (Bcl-2) family of proteins, cooperate in causing bone marrow and gastrointestinal tract toxicity in response to chemo and radiation therapy. Deletion of both Puma and Bim provides long-term survival without evidence of increased tumor susceptibility following a lethal challenge of carboplatin and ionizing radiation. Consistent with these in vivo findings, studies of primary mast cells demonstrated that the loss of Puma and Bim confers complete protection from cytokine starvation and DNA damage, similar to that observed for Bax/ Bak double knockout cells. Biochemical analyses demonstrated an essential role for either Puma or Bim to activate Bax, thereby leading to mitochondrial outer membrane permeability, cytochrome c release and apoptosis. Treatment of cytokine-deprived cells with ABT-737, a BH3 mimetic, demonstrated that Puma is sufficient to activate Bax even in the absence of all other known direct activators, including Bim, Bid and p53. Collectively, our results identify Puma and Bim as key mediators of DNA damageinduced bone marrow failure and provide mechanistic insight into how BH3-only proteins trigger cell death.
that can also directly trigger the activation of the pro-apoptotic effectors Bax and Bak. 6 The tumor suppressor p53, which initiates apoptosis through the transcriptional upregulation of Puma, Noxa and other target genes, has also been reported to antagonize Bcl-2, Bcl-X L and Mcl-1, and to directly activate Bax/Bak. [7] [8] [9] Similarly, Puma may also act as a direct activator of Bax and Bak. 10 We have taken a genetic and biochemical approach using knockout mice and primary cell lines to test the functional requirements of Puma, Bim, Bid and p53, the only known putative direct activators of Bax and Bak, in the induction of apoptosis. We report here that Puma and Bim cooperate in the activation of Bax/Bak in response to signals that trigger both p53-dependent and p53-independent cell death. Deletion of Puma and Bim protected mice long term without a significant increased risk of cancer from a lethal myelosuppressive regimen of carboplatin and ionizing radiation. Moreover, Puma À/À /Bim À/À double knockout (DKO) primary bone marrow cells expanded in culture remained viable when deprived of growth factors and treated with irradiation (IR) or the BH3-mimetic drug ABT-737. The extent of survival was equivalent to that observed for Bax À/À /Bak À/À cells. By contrast, cells lacking Bim, Bid and p53 either individually or collectively remained sensitive to growth factor deprivation and ABT-737 treatment. Our results demonstrate that the BH3-only protein Puma is sufficient to induce Bax/Bak activation even in the absence of all other known direct activators. Most importantly, our findings provide a proof-ofprinciple that BH3 antagonists (e.g. small molecule inhibitors) could be developed to alleviate hematological toxicities commonly associated with cancer therapies without significantly increasing the risk of secondary malignancies.
Results
Cooperation of Puma and Bim in therapy-induced lethal myelosuppression. Previous studies demonstrated that the pathogenicity and mortality associated with the lethal myelosuppressive regimen of carboplatin plus g-IR could be circumvented either by the deletion of the tumor suppressor p53 or by the immediate treatment of the mice with recombinant cytokine thrombopoietin (TPO) post-therapy. p53-deficient mice are presumably resistant to the myelosuppression regimen due to a failure to upregulate pro-apoptotic target genes, such as Puma, or to trigger cell death by directly activating Bax. TPO likely protects the hematopoietic compartment through the upregulation of the pro-survival proteins Bcl-2, Bcl-X L and Mcl-1, which inhibit apoptosis by preventing Bax/Bak from inducing MOMP. 12, 13 Furthermore, TPO may have a protective role by suppressing the expression of pro-apoptotics, such as Puma and Bim. To begin challenging these hypotheses, wild-type (WT),
/Bim À/À mice were treated with carboplatin (80 mg/kg) immediately followed by 7.5 Gy total body IR and monitored for survival and recovery of hematopoiesis over time (Figure 1) . Consistent with previous studies, all WT animals died by day 15 (median survival 12.5 days) due to bacteremia resulting from gastrointestinal (GI) damage, in combination with bone marrow failure (Supplementary Figure 1) . Essentially, the damage to the GI tract leads to a breach in the colonic barrier, allowing resident bacteria to escape. Since the combined treatment immunocompromises the mice, they are unable to mount an effective immune response; hence, the animals develop disseminated bacteremia throughout a variety of tissues including the lungs, kidney and heart (Supplementary Figure 1 and data not shown). Similarly, the Bim À/À mice were also sensitive to colonic damage and myelosuppression and succumbed to bacteremia with a median survival of 13 days. The Puma À/À mice were remarkably resistant and 100% survived 4 weeks after treatment, most likely due to maintaining GI tract integrity (Supplementary Figure 1) ; however, B40% of the animals died between days 55 and 77 due to carditis, atherosclerosis, arteriosclerosis and unknown causes. By contrast, Puma À/À /Bim À/À DKO mice were completely protected and survived long term without significant sequelae or increased tumor susceptibility (Figure 1a ) when compared with untreated Puma À/À /Bim À/À mice, which spontaneously develop lymphomas and sarcomas by B1 year of age.
14 Bone marrow recovery was determined by assaying white blood cells (WBCs), platelets and hemoglobin in peripheral blood every 5 days after treatment (Figure 1b ). All animals, regardless of genotype, displayed a sharp decrease in each of these parameters within the first 2 weeks. However, the Puma À/À and Puma À/À /Bim À/À mice began recovering WBC, platelets and hemoglobin by day 15, whereas the WT and Bim À/À mice failed to restore hematopoiesis and died because of an insufficient immune response to bacteremia caused by GI syndrome. These results suggest that loss of Puma alone is adequate for protecting bone marrow progenitors and intestinal cells from DNA damage, and that combined deletion of Puma and Bim is required for long-term survival postchemo and radiation therapy. 
/

Bim
À/À mice were expanded in tissue culture in the presence of IL3, IL6 and stem cell factor (SCF) as previously described, resulting in Sca þ , cKit þ , LinÀ cell populations. 15, 16 Detailed phenotype analyses demonstrated that the primary cells express FceR1 and MC-protease-5 (mMCP-5), but not MC-protease-1 (mMCP-1), which is indicative of connective tissue mast cells (CTMCs; Supplementary Figure 2) . 17 Notably, deletion of Bim and/or Puma did not alter differentiation, resulting in the expansion of identical myeloid cell types regardless of genotype. Primary CTMCs require cytokines for proliferation and survival, and during growth factor starvation undergo G1 cell-cycle arrest and apoptosis in a p53-independent manner. Cell death during cytokine deprivation is accelerated by ionizing radiation and other DNA damaging agents, which occurs through a p53-dependent apoptotic mechanism. Bid is dispensable for myeloid apoptosis during growth factor withdrawal and DNA damage. Bid, a pro-apoptotic BH3-only protein commonly associated with the extrinsic apoptotic pathway, activates Bax to induce apoptosis. 19 It has also been reported that the p53 tumor suppressor has a similar role in triggering cell death through Bax activation. [7] [8] [9] To address the role of these putative 'direct activators' in myeloid cell death during cytokine deprivation plus IR, In support of this observation, truncated Bid was not detected under these culture conditions (data not shown). The p53/Bid/Bim TKO primary myeloid cells were highly resistant to cytokine deprivation with or without IR, presumably due to the loss of Bim, p53 and indirectly Puma, which compromises the growth factor withdrawal-and DNA damage-induced apoptotic responses, respectively (Supplementary Figure 3) . Together, these results demonstrate that the loss of p53 and Bim is sufficient to inhibit programmed cell death in these models of limiting cytokines and genotoxic stress. , Puma À/À and Puma À/À /Bim À/À primary CTMCs that were deprived of cytokines and/or subjected to IR at 16 h after treatment. Samples were subjected to immunoprecipitation using antibody 6A7, which is specific for the conformation-altered form of activated Bax, followed by western blot analysis (Figure 4a 
Discussion
We addressed the physiological functions of Puma and Bim and the mechanisms by which they induce cell death using genetically engineered mouse models. Previous studies examining the loss of Puma, Bim or in combination have demonstrated that these proteins are mostly redundant in the context of growth factor withdrawal or glucocorticoid treatment in mast, T and B cells. 14, 22 However, our results clearly demonstrate that Bim À/À and Puma À/À mice respond differently to carboplatin and IR-induced lethal myelosuppression. Puma knockouts were highly resistant to both GI syndrome and hematopoietic failure with 100% of the animals surviving past 30 days, whereas WT and Bim-deficient mice displayed marked hyperplasia in the colon with systemic bacteremia, in combination with a failure to recover hematopoiesis and died within 2 weeks of treatment (Figure 1 ). In support of this finding, two independent studies demonstrated that the loss of /Bak À/À CTMCs were cultured in the presence or absence of cytokines for 6 h, permeablized in 0.015% digitonin and treated with C8-Bid (25 nM), Puma or Bim peptide (10 mM) or ABT-737 (0.75 mM) for 75 min. Cytochrome c release was determined by western blot analysis and actin was used as a loading control. Representative blot from three independent experiments is presented Puma conferred a similar survival advantage during high-dose IR due to hematopoietic stem cell protection. 23, 24 However, as we show here, deletion of both Puma and Bim was required for long-term survival, suggesting that each may have a defined role in hematopoietic stem and/or progenitor cells.
Cytokine signaling pathways maintain elevated levels of Bcl-2, Bcl-X L and Mcl-1, while limiting the expression of Puma, Bim and other pro-apoptotics. Therefore, cytokine withdrawal sensitizes primary cells to apoptosis by altering the balance between pro-survival and pro-apoptotic proteins. Puma À/À / Bim À/À cells deprived of cytokines express lower levels of Bcl-X L and Mcl-1, but maintain viability, demonstrating that the decrease in Bcl-X L and Mcl-1 occurs independently of binding to Bim or Puma, and cell death (Figures 2 and 3) . Primary CTMCs deprived of cytokines and treated with IR undergo p53-dependent apoptosis. Although deletion of Bim or Puma conferred only partial protection, Puma À/À
/Bim
À/À cells were completely resistant to cytokine starvation and IR due to a failure to activate Bax and MOMP ( Figure 4 and data not shown). The DKO cells remain completely viable, but undergo cell-cycle arrest and efficiently resume DNA synthesis when restimulated with cytokines ( Figure 2c ). Consistent with these results, recombinant TPO, or the deletion of either p53 or Puma, fully protects mice from a lethal myelosuppressive regimen of carboplatin and IR (Figure 1) . 11 These findings establish a clinically relevant link between cytokines, DNA damage and p53 signaling pathways.
The p53 tumor suppressor induces apoptosis through the transcriptional induction of downstream target genes, such as Puma, Noxa and Bax. 25 It has also been proposed that p53 directly activates Bax and this transcription-independent proapoptotic activity is inhibited by binding to Bcl-2, Bcl-X L and Mcl-1. [7] [8] [9] In this model, the induction of Puma during cellular stress competitively binds Bcl-X L , which free p53 to activate Bax and trigger apoptosis. 9 As shown in Figure 5b , TKO primary CTMCs deficient in Bid, Bim and p53 underwent apoptosis to the same extent as WT cells when deprived of cytokines and treated with ABT-737, demonstrating that these three putative direct activators of Bax are dispensable for cell death under these conditions. In light of these results and the findings that Puma/Bim DKO cells are completely resistant to cytokine starvation plus ABT-737 (Figure 5a) , we propose that endogenous Puma is sufficient to activate Bax in vivo (Figure 5c ). In support of this conclusion, recent studies have reported a direct interaction between Puma with Bax in cellfree systems and yeast. 26, 27 Puma À/À /Bim À/À primary CTMCs provided a unique opportunity to challenge the 'direct activator/derepressor' versus 'neutralization' models of Bax activation utilizing the BH3-mimetic drug ABT-737. 19 We hypothesized that if the neutralization model was operative, then treatment of Puma À/À /Bim À/À cells with ABT-737 in the absence of cytokines should induce apoptosis by releasing Bax and Bak from sequestration by the anti-apoptotic Bcl-2 family members. Although Mcl-1 protects cells from apoptosis mediated by ABT-737, [28] [29] [30] our data demonstrate that the expression of this anti-apoptotic protein is markedly diminished upon cytokine withdrawal. Furthermore, WT cells deprived of cytokines and treated with ABT-737 rapidly underwent apoptosis, suggesting that Mcl-1 and other survival factors, such as A1, are not sufficient to block MOMP and cell death. By contrast, Puma À/À /Bim À/À cells were completely protected from Bax activation and apoptosis, demonstrating an essential role for Bim and Puma in triggering cell death. Our findings provide genetic and biochemical evidence in support of the direct activator/derepressor model of apoptosis. [19] [20] [21] Similar results and conclusions have been generated using Bid
/Puma
À/À TKO mice and primary cells. 31 Puma expression is naturally selected against during lymphomagenesis in c-Myc transgenic mice and primary human Burkitt lymphomas. 32, 33 Therefore, restoring Puma apoptotic function would be a reasonable goal for treating specific malignancies, and BH3 mimetics (e.g. ABT-737, SAHBs) could provide such an opportunity. 26, 34 Interestingly, Strasser and Villunger recently reported the surprising findings that Puma deficiency suppresses lymphomagenesis in response to low-dose, fractionated ionizing radiation, raising the cautionary flag that BH3 mimetics could promote secondary malignancies in the context of cancer therapies. 35, 36 Our studies complement these findings and show that Puma deficiency also protects against a lethal dose of carboplatin and ionizing radiation without increasing tumor susceptibility.
In summary, we demonstrated that Puma and Bim cooperate in activating Bax, MOMP and apoptosis both in vitro and in vivo in response to cell stress. We also provided mechanistic insight into how these pro-apoptotic BH3-only proteins trigger cell death, supporting the 'direct activator' of apoptosis model. Most importantly, we identified Puma and Bim as key targets that limit chemo and radiation therapy due to GI syndrome and bone marrow toxicity. These findings provide a proof-of-principle that BH3 antagonists, such as small molecule inhibitors, could be developed to protect hematopoiesis and the GI tract from DNA damaging agents commonly used in cancer treatments without significantly increasing susceptibility to secondary malignancies. Given the scope of Puma in other pathological diseases, such as heart ischemia, stroke and neurodegeneration, the application of BH3 antagonists could have broader clinical implications. . BH3 domain peptides, Bim, and PUMA, sequences as described. 37 Peptides were resuspended in anhydrous DMSO, stored at À80 1C, and thawed only once.
Animals. Puma
À/À (C57BL6/SV129 mixed) mice were previously reported.
15
Bim À/À (C57BL6/SV129 mixed) mice were a kind gift from Andreas Strasser (WEHI) and have been reported elsewhere. 38 The Bid À/À (C57BL6/SV129 mixed) and conditional Bax/Bak knockout mice were generously provided by Stanley Korsmeyer and have been reported elsewhere. 39 Myelosuppressive regimen. Mice were given 80 mg/kg carboplatin (SICOR Pharmaceuticals, Inc., Irvine, CA, USA) intravenously immediately followed by 7.5 Gy total body ionizing radiation for the indicated period while on the antibiotic Baytril.
11 All mice were observed daily for signs of morbidity and tumor development. Tissues from morbid or moribund mice were fixed in 4% paraformaldehyde for subsequent histopathological evaluation.
Blood counts. Blood was collected into EDTA-coated 20 l microcapillary tubes (Fisher Scientific, Pittsburgh, PA, USA). WBC counts, hemoglobin concentration and platelet counts were determined using a FORCYTE Hematology System (Oxford Science, Inc., Oxford, CT, USA).
Bone marrow-derived primary myeloid cell isolation, culture and treatment. Bone marrow was isolated from the hind femur and tibias of WT, Bim
/Bim À/À mice. Primary myeloid cells were consequently generated as described elsewhere and cultured in RMPI-1640 supplemented with 15% FBS, 1% P/S, 10 mM glutamine, 10 ng/ml mouse recombinant SCF (R&D), 10 ng/ml mouse recombinant IL-6 (R&D) and 40 U/ml mouse recombinant IL-3. 15, 16 Following 3 weeks of culture with regular changes of media, the immunophenotype was determined by flow cytometry. Established homogenous cultures of bone marrow-derived cells were Sca-1 þ cKit þ , negative for F4/80, GR-1/Ly6G, CD4, CD8, B220 and Ter-119 and positive for FcR1. Primary CTMCs were washed twice with HBSS and resuspended in cytokine-free media before IR (5 Gy) exposure or ABT-737 (1 mM). Cells were incubated for indicated time periods and cell responses compared with cells cultured in the presence of cytokines.
Cell viability and apoptosis determination. Cell concentration and viability was evaluated by trypan blue exclusion utilizing a Vi-CELL automated analyzer (Beckman Coulter, Brea, CA, USA). Apoptosis was determined by flow cytometric evaluation of the AnnexinV-positive population. Samples were washed twice with ice-cold PBS and stained with AnnexinV-APC and 7-AAD according to the manufacturer's instructions (BD Biosciences, San Jose, CA, USA).
Protein isolation and western blot analysis. Cells were harvested, washed in PBS and resuspended in CHAPS buffer (1% CHAPS, 10 mM HEPES, pH 7.4, 150 mM NaCl) containing Complete Mini protease inhibitor pill (Roche, Applied Science, Indianapolis, IN, USA), phosphatase inhibitors and 1 mM PMSF (SigmaAldrich). The lysates were incubated on ice for 30 min and supernatants harvested following centrifugation at 13 000 Â g for 15 min. Protein concentrations were determined by the BCA assay (Thermo Scientific, Rockford, IL, USA) as described by the manufacturer's instructions. Protein expression (50 mg/lane for both cellular and isolated mitochondria experiments) was determined by SDS-polyacrylamide gel electrophoresis (PAGE) and subsequent western blot analysis (Invitrogen, Carlsbad, CA, USA). Western blot filters were probed with the indicated primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies (KPL, Inc., Gaithersburg, MD, USA). Proteins were visualized using the enhanced chemiluminescence (ECL) system (Thermo Scientific) followed by exposure to CL-Xposure films (Kodak, Rochester, NY, USA).
Immunoprecipitation of activated Bax. To detect the active form of Bax, primary CTMCs were collected and lysed in CHAPS lysis buffer on ice. Briefly, activated Bax was immunoprecipitated from 500 mg of whole cell lysates with the monoclonal antibody clone 6A7 (Sigma-Aldrich), which reacts only with Bax in its conformationally active state, and Protein G Sepharose 4 Fast Flow Beads (Amersham, Little Chalfont, UK). Isolated active Bax samples were then subjected to western blot analysis and identified with a rabbit polyclonal anti-Bax (N-20; Santa Cruz Biotechnology) antibody and ECL as described above.
Cellular permeablization and MOMP analysis. Primary CTMCs (5 Â 10 6 /sample) were collected, washed in PBS and incubated on ice for 5 min in permeability buffer (20 mM HEPES, pH 7.2, 100 mM KCl, 5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 250 mM sucrose and 0.015% digitonin from 10% DMSO stock) containing Complete Mini protease inhibitor pill. Proteins, peptides and ABT-737 (final concentrations indicated in the figure legends) were then added and the cells were incubated at 30 1C for 1.25 h. Samples were centrifuged for 10 min in 4 1C at 15 000 Â g. Supernatants were collected and analyzed by SDS-PAGE and western blot with anti-cytochrome c (clone 7H8.2C12).
BrdU incorporation. Primary myeloid cells were labeled with 10 mM 5-bromo-2 0 -deoxy-uridine (BrdU) for 24 h at 37 1C under aseptic conditions. Cells were harvested and BrdU incorporation was determined using the 'APC BrdU Flow Kit' according to the manufacturer's instructions using a FACScalibur flow cytometer (BD Biosciences).
